Company intelligence / Profile preview

Abalos Therapeutics

Düsseldorf, North Rhine-Westphalia, Germanyabalos-tx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Abalos’ lead candidate ABX-001 has demonstrated marked tumor regression and induction of tumor-specific T cells in preclinical models with an excellent safety profile. The company plans to initiate first-in-human trials in solid tumors in 2025[1][5]. No clinical results are available yet.

Therapeutic areas: Oncology
Modalities: Arenavirus-based immuno-virotherapeutics (novel viral immunotherapies)
Industry: Biotech

Drug pipeline

3 assets

ABX-001

2 more assets in the full pipeline.

Request access →

Partnerships

Not explicitly listed; investors include Boehringer Ingelheim Venture Fund which may indicate strategic relationships[6].

Beyond the preview

Go deeper on Abalos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abalos Therapeutics.

Explore the full profile